<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04525807</url>
  </required_header>
  <id_info>
    <org_study_id>2020-08</org_study_id>
    <nct_id>NCT04525807</nct_id>
  </id_info>
  <brief_title>Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella Theory</brief_title>
  <official_title>Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella Theory</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to more accurately discover the cause of drug resistance in tumor treatment, and to&#xD;
      provide a new basis for precise treatment.&#xD;
&#xD;
      Therefore, based on the umbrella theory of precision medicine, we carried out this&#xD;
      single-center, prospective, and observational study to include patients with liver metastases&#xD;
      from colorectal cancer. By combining genome, transcriptome, and proteomic sequencing data, we&#xD;
      established a basis for colorectal cancer liver Transfer the multi-omics data of the sample,&#xD;
      describe the reason for the resistance of the first-line treatment, and search for new&#xD;
      therapeutic targets.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>1 year</time_frame>
    <description>Refers to the proportion of patients whose tumors have shrunk to a certain amount and maintained for a certain period of time, including complete remission (CR) and partial remission (PR) cases</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Refers to the date from initial diagnosis to tumor progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Refers to the date from initial diagnosis to last follow-up or death date</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Multiomics arm</arm_group_label>
    <description>Guide therapy based on multi-omics</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Multi-omics</intervention_name>
    <description>Use multi-omics to analyze</description>
    <arm_group_label>Multiomics arm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who were newly diagnosed with liver metastases from colorectal cancer&#xD;
        (pathologically diagnosed as adenocarcinoma)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ECOG score 0-2 points&#xD;
&#xD;
          -  Pathologically diagnosed patients with colorectal cancer&#xD;
&#xD;
          -  Combined with liver metastases confirmed by imaging, and the lesion is measurable&#xD;
             (RECIST standard)&#xD;
&#xD;
          -  The lesion is available&#xD;
&#xD;
          -  First-line treatment failed; hematology, liver and kidney function tests are suitable&#xD;
             for back-line treatment&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  With brain metastases&#xD;
&#xD;
          -  History of other malignancies&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Have received other drug clinical studies within 30 days before the start of this&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 21, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2020</study_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

